Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Pegfilgrastim (Neulasta)
DRUG
3 trials
Sponsors
M.D. Anderson Cancer Center
, Coherus Oncology, Inc.
, Yonsei University
Conditions
Immunity, Humoral
Multiple Myeloma
Triple-Negative Breast Cancer
Phase 1
Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®
Completed
NCT02418104
Coherus Oncology, Inc.
Immunity, Humoral
Start: 2015-05-31
End: 2015-12-31
Updated: 2016-01-07
Phase 2
Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma
Completed
NCT00067639
M.D. Anderson Cancer Center
Multiple Myeloma
Start: 2003-12-31
End: 2007-04-30
Updated: 2012-08-01
Unknown Phase
An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy
Recruiting
NCT07525869
Yonsei University
Triple-Negative Breast Cancer
Start: 2025-10-28
End: 2026-10-27
Target: 40
Updated: 2026-04-20
Related Papers
Biosimilar Pegfilgrastim-cbqv Demonstrated Similar Immunogenicity to Pegfilgrastim in Healthy Subjects Across Three Randomized Clinical Studies.
2022-01-16
4 citations